Groupement Des Hopitaux De L'Institut Catholique De Lille — Clinical Trial Site

73 Registered trials

25 Currently recruiting

Organisation

Groupement Des Hopitaux De L'Institut Catholique De Lille

Location

Lille Cedex, France

Identifier

ORG-100031463

Address

Boulevard De Belfort, P. O. Box 387, 59020, France

Departments

#1215:Neurology
#2110: Neurology
#8308: Rhumatologie
7004:Neurology
7005:Service de Rhumatologie
a
Département d'Onco-Hématologie
Dermatology
HEMATOLOGIE
Hématologie option maladies du sang
Hematology
Hematology Department
Hôpital Saint Vincent de Paul - Service d'onco-hématologie clinique
Hôpital Saint Vincent-de-Paul, Onco-hématologie
Medecine nucleaire
Neurologie
Neurology
Onco-Hématologie
Onco-hematology
Oncologie - Hématologie
Oncologie Médicale
Pneumologie
Réanimation
Rheumatology
Rhumatologie
Rhumatology
Service d'infectiologie
Service d'onco-hématologie
Service d’onco-Hématologie
Service de dermatologie
Service de Neurologie - Unité Neurovasculaire
Service de pédiatrie médicale et urgences pédiatriques
Service de Pneumologie
Service de Rhumatologie
Service Hématologie
Service neurologie
Urologie

Clinical trials at this site (73)

Search interface

Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit… Recruiting

2024-510981-18-00 Multiple Myeloma Multiple myeloma (MM) is a B cell mali 5 2024-12-12
Design and evaluation of an individualized biodrug tapering strategy based on biodrug dosage: the MONITORA study_STEP1 Recruiting

2024-514313-35-00 Arthritis rheumatoid 6 2024-12-03
Multicenter randomized, double-blind, placebo controlled trial evaluating the effect of a 30-week caffeine treatment on cognition in early-t… Recruiting

2024-514099-41-00 Alzheimer's disease 5 2024-10-31
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab … Recruiting

2022-501554-11-00 Patients with previously untreated Richter’s syndrome ( 4 2024-03-21
A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part… Recruiting

2022-503092-28-00 Relapsed/Refractory Follicular Lymphoma 5 2024-01-08
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare Recruiting

2024-518844-20-00 Treatment of Acute Gout Flare 10 2023-10-03
Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting

2022-501710-62-02 Peripheral T-cell lymphoma (PTCL) 6 2023-06-07
RIISC Recruiting

2024-513669-38-00 Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis 5 2023-05-17
Efficacy of a sequential treatment strategy in Rheumatoid Arthritis. Recruiting

2022-500234-29-00 Rheumatoid Arthritis 5 2022-11-28
IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre… Recruiting

2024-517215-67-00 Newly diagnosed Non-Frail transplant Ineligible Multipl 5 2021-06-11
Avoid Anticoagulation After IntraCerebral Haemorrhage Recruiting

2024-514094-22-00 Intrecerebral Haemorrhage 5 2019-01-18
RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASAL… Recruiting

2024-516704-41-00 Rheumatoid Arthritis 11 2016-03-30
Phase 3 trial aimed at improving the overall survival of AML in adults aged 18 to 60 by comparing high-dose idarubicin with daunorubicin at … Ended

2024-516873-57-00 Acute myeloid leukemia in adults aged 18 to 60 10 2026-01-13
A Phase 3 Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 Years of Age With Severe Alopecia Areata Ended

2024-515438-33-00 Alopecia areata 5 2026-01-12
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu… Ended

2024-510965-41-00 Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymph 5 2024-09-03
A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended

2023-510178-15-00 High-risk Large B-cell Lymphoma 5 2024-07-31
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Ended

2023-508235-31-00 Atopic Dermatitis 5 2024-06-17
Study of safety and efficacy of ONUREG in combination with VENETOCLAX in higher-risk myelodysplastic syndromes ineligible for allogenic tran… Ended

2024-514876-41-00 Higher-risk myelodysplastic syndromes untreated and ine 9 2023-12-06
TRIO: A prospective randomized Trial of non-inferiority comparing RItuximab versus Ocrelizumab in relapsing-remitting multiple sclerosis. Ended

2022-501027-25-01 Multiple Sclerosis 11 2023-06-01
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas… Ended

2023-503444-13-00 Relapsed/refractory multiple myeloma 5 2023-03-29
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
VERLEN - Phase II, Open-Label Study evaluating efficacy of Lenalidomide and Tafasitamab combination associated to Rituximab in frontline Dif… Ended

2023-507286-25-00 Diffuse Large B-Cell Lymphoma 4 2021-12-23
FILOCLL14 - STAIR : "Open-label, phase 2 study investigating the STop and restart Acalabrutinib In fRrail patients with previously untreated… Ended

2024-513936-80-00 elderly patients (> 70 years) with CLL or SLL 4 2021-11-12